Physician profile
Maureen E Caro
NPI 1043501604
$560.72
in general payments reported to CMS, 2019-2025
13 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $144 · 2024: $190 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.99 | 2023-2025 | |
| Gilead Sciences, INC. | $131.96 | 2023-2025 | Descovy |
| Corium, LLC | $81.95 | 2025 | Azstarys |
| Lilly USA, LLC | $30.92 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $29.37 | 2024-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $25.73 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $23.87 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Sanofi Pasteur INC. | $17.49 | 2024 | |
| Hologic Sales and Service, LLC | $17.29 | 2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $15.04 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $14.86 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2023 | Uzedy |
| Noven Therapeutics, LLC | $13.16 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.